FDA Panel: Yank Keytruda Approval in Third-Line Gastric Cancer

(MedPage Today) -- An advisory committee recommended that the FDA revoke the accelerated approval for pembrolizumab (Keytruda) as a third-line option in gastric or gastroesophageal junction (GEJ) cancer.
With a vote of 6-2, the Oncologic Drugs...